Bupropion Co-Administration for Dextromethorphan Metabolism Control
Solution Overview
Problem
Dextromethorphan is rapidly metabolized in the liver, leading to low plasma levels in extensive metabolizers, limiting its clinical utility, and existing treatments do not effectively address adverse events or metabolic issues.
Innovation Solution
Co-administration of bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion with dextromethorphan to inhibit metabolism, increase plasma levels, and reduce adverse events, using a combination that includes a sustained release delivery system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If dextromethorphan is administered to extensive metabolizers, then therapeutic effect is achieved, but plasma levels are low due to rapid metabolism
Solution Approach 1:
Bupropion is introduced as an intermediary substance that inhibits the metabolic breakdown of dextromethorphan. By co-administering bupropion with dextromethorphan, the plasma levels of dextromethorphan are increased without directly altering the metabolism itself, thus resolving the contradiction between achieving therapeutic effect and maintaining adequate plasma levels in extensive metabolizers
Solution Approach 2:
The invention changes the pharmacokinetic parameter of dextromethorphan metabolism by introducing an inhibitory agent (bupropion). This parameter change slows down the metabolic rate, thereby increasing plasma levels and extending the duration of action, which directly addresses the issue of rapid metabolism in extensive metabolizers
2Quantity of substance
If dextromethorphan is administered frequently to maintain plasma levels, then therapeutic efficacy is maintained, but dosing frequency increases and convenience decreases
Solution Approach 1:
Bupropion serves as a mediator that extends the duration of action of dextromethorphan by inhibiting its metabolism. This allows for reduced dosing frequency while maintaining therapeutic plasma levels, thereby improving ease of operation without compromising therapeutic efficacy
Solution Approach 2:
By using bupropion to inhibit metabolism, the invention achieves a partial extension of dextromethorphan's half-life. This partial action is sufficient to reduce dosing frequency from multiple times daily to once or twice daily, making the regimen more convenient while maintaining adequate plasma levels
3Quantity of substance
If dextromethorphan is administered at high doses to increase plasma levels, then therapeutic effect is improved, but adverse events increase
Solution Approach 1:
Bupropion acts as an intermediary that increases dextromethorphan plasma levels through metabolic inhibition rather than dose increase. This approach achieves therapeutic plasma levels without the associated adverse events that would result from administering higher doses of dextromethorphan alone
Solution Approach 2:
Instead of increasing the dose (mechanical approach), the invention uses a biochemical mechanism (metabolic inhibition by bupropion) to achieve the same therapeutic effect. This substitution allows for achieving therapeutic plasma levels without the harmful effects associated with high-dose administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances dextromethorphan plasma levels, reduces metabolic breakdown, and decreases adverse events, allowing for less frequent dosing without loss of efficacy, thereby improving therapeutic efficacy and safety.
Implementation Method 1
Co-administration of bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion with dextromethorphan to inhibit metabolism, increase plasma levels
Data Source
AI summary
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.



